Trial Profile
A Phase II, Multicenter Study of Eribulin Evaluating Efficacy and Safety in Patients with Taxane-resisted Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 16 Feb 2015 Status changed from recruiting to completed, according to University Hospital Medical Information Network - Japan
- 09 Jan 2012 New trial record